escitalopram / Generic mfg. - LARVOL DELTA

A Rare Case of Therapeutic Amphetamine-Dextroamphetamine-Induced Ischemic Colitis in a Middle-Aged Woman Without Traditional Vascular Risk Factors (ACG 2026) - "Amphetamine-dextroamphetamine (Adderall), commonly prescribed for ADHD, has rarely been implicated...Medications included amphetamine-dextroamphetamine ER 15 mg daily, semaglutide, escitalopram, clonidine, and rosuvastatin...The medication was discontinued, and the patient improved with IV fluids, ceftriaxone, and metronidazole...As prescription stimulant use increases, clinicians should remain aware of this rare adverse effect, as early recognition and discontinuation of the offending agent may prevent recurrent ischemia and complications. Figure: Ischemic-type changes characterized by hyalinization of the lamina propria (highlighted by the Sirius red stain), surface erosion, withering crypts and focal pseudomembranous exudates Figure: Segmental mucosal friability and ulcerative ischemic injury involving the sigmoid colon"

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Cognitive Disorders • Endometriosis • Gastroenterology • Gastrointestinal Disorder • Gynecology • Hematological Disorders • Immunology • Inflammation • Women's Health

Tirzepatide-Associated Drug-Induced Liver Injury in a Liver Transplant Recipient: A Case Report (ACG 2026) - "She has been on 5 mg of extended-release tacrolimus (envarsus) daily with stable therapeutic trough levels. Review of other medications was notable for allopurinol, escitalopram, and glipizide, which were long-term with stable dose...Figure: Table 1. Liver Enzyme Trends During Tirzepatide Exposure and Following Discontinuation"

Case report • Clinical • Diabetes • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Transplantation • Type 2 Diabetes Mellitus

SSRI Use in Irritable Bowel Syndrome and Its Impact on Disease Outcomes: A Propensity-Matched Real-World Cohort Study (ACG 2026) - "Cohort 1 received an SSRI (sertraline, escitalopram, citalopram, fluoxetine, or paroxetine) within 1 year of diagnosis without concurrent TCA use. Post-matching cohorts were well-balanced (79.7% female, ~80% White). SSRI use was associated with lower functional symptom persistence (57.0% vs. 60.7%; RR 0.94, 95% CI 0.93-0.94; p< 0.001; median time-to-recurrence 589 vs."

Clinical • Real-world • Real-world evidence • CNS Disorders • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Mood Disorders • Ulcerative Colitis

Psychological and neurobiological outcomes of combined rTMS and robotic therapy in post-stroke depression: A randomized controlled study. (PubMed, Acta Psychol (Amst)) - "Ninety eligible inpatients with PSD were randomized equally to an experimental group receiving 10-Hz rTMS plus robot-assisted rehabilitation and conventional rehabilitation, or to a control group receiving escitalopram plus conventional rehabilitation, for four weeks...These findings suggest that combined rTMS and intelligent robot-assisted rehabilitation is a feasible non-pharmacological intervention for PSD and may improve both psychological and functional outcomes, potentially through enhanced neuroplasticity and reduced inflammatory activity. Larger multicenter randomized trials with sham-control arms and longer follow-up are needed to confirm efficacy, durability, and mechanisms."

Journal • Cardiovascular • CNS Disorders • Depression • Mood Disorders • Psychiatry • BDNF • IL6 • TNFA

Irritability and Emotion Dysregulation Predict Escitalopram Response in Adolescents with Generalized Anxiety Disorder: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. (PubMed, J Child Adolesc Psychopharmacol) - "Irritability is associated with clinical response in adolescents with GAD. Child- and parent-reported irritability predicted treatment response independent of baseline anxiety severity, while reductions in irritability paralleled improvement in anxiety. These findings suggest that irritability may represent a clinically important aspect of illness and a potential treatment target in pediatric anxiety disorders."

Clinical • Journal • CNS Disorders • General Anxiety Disorder • Mood Disorders • Pediatrics • Psychiatry

QTc changes and early major adverse cardiovascular events associated with antidepressant treatment for major depressive disorder in adults: individual participant data network meta-regression of double blind randomised trials. (PubMed, BMJ) - "The effect of specific antidepressants on QTc interval differed between adults with depression. No evidence associated antidepressant use with early MACE and non-suicidal sudden death. To support shared decision making and taking into account the trade-off between benefits and harms, individual modifiable and non-modifiable risk factors should be considered when choosing antidepressants."

Adverse events • Clinical • Journal • Cardiovascular • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Adverse event reporting patterns of selective serotonin reuptake inhibitors (SSRIs): disproportionality analysis using the European spontaneous reporting system. (PubMed, Eur Arch Psychiatry Clin Neurosci) - "SSRIs showed homogeneous adverse event reporting patterns, with relatively few differences in disproportional reporting between individual drugs. These results reinforce the importance of continuous pharmacovigilance monitoring."

Adverse events • Journal • CNS Disorders • Mental Retardation • Pain • Psychiatry • ROR1

Escitalopram for Depression and Motor Symptoms in Parkinson’s Disease: A Systematic Review and Meta-analysis (MDS Congress 2026) - No abstract available

Retrospective data • Review • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Escitalopram Discontinuation-Related "Brain Zaps" in a Patient With Generalized Epilepsy. (PubMed, J Clin Psychopharmacol) - No abstract available

Journal • CNS Disorders • Epilepsy

Home-TEA: Home Transcutaneous Electrical Acustimulation (TEA) (clinicaltrials.gov) - P2/3 | N=160 | Recruiting | Sponsor: University of Michigan | Trial completion date: Sep 2026 ➔ Mar 2027 | Trial primary completion date: Sep 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Constipation • Gastroenterology • Gastrointestinal Disorder • Pain

Mechanisms of Precision Deep Transcranial Magnetic Stimulation Therapy for Suicidal Ideation in Adolescent Depressive Disorder: A Study Based on Causal Analysis of Multimodal Brain Networks (ChiCTR) - P=N/A | N=126 | Not yet recruiting | Sponsor: The First Hospital of Hebei Medical University; The First Hospital of Hebei Medical University

New trial • CNS Disorders • Depression • Mood Disorders • Psychiatry • Suicidal Ideation

A Study of Probiotic Powder as an Add-on Treatment for Depression With Anhedonia (ChiCTR) - P=N/A | N=78 | Not yet recruiting | Sponsor: Beijing An Ding Hospital, Capital Medical University; Beijing An Ding Hospital, Capital Medical University

New trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Development of nanoemulsion-based in situ gel formulation of escitalopram oxalate for intranasal delivery in depression therapy. (PubMed, Daru) - "The optimized nanoemulsion-based in situ gel demonstrated sustained drug release, enhanced nasal permeation, acceptable safety, and improved antidepressant efficacy. These findings indicate that the developed formulation is a promising non-invasive platform for intranasal delivery of escitalopram oxalate with the potential to enhance nose-to-brain delivery for depression therapy."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Replication of sensory anhedonia as a predictor of escitalopram response: evidence from the NeuroPharm study. (PubMed, Psychol Med) - No abstract available

Journal • CNS Disorders • Depression • Psychiatry

LYMPHODEP: Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants (clinicaltrials.gov) - P=N/A | N=50 | Completed | Sponsor: Germans Trias i Pujol Hospital | Trial completion date: Jul 2027 ➔ Jul 2026 | Trial primary completion date: Dec 2026 ➔ Jun 2026 | Not yet recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Inflammation • Mood Disorders • Psychiatry

Escitalopram and the Risk of Serious Adverse Events (clinicaltrials.gov) - P=N/A | N=12145 | Active, not recruiting | Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed ➔ Active, not recruiting | Trial completion date: Nov 2025 ➔ Dec 2027

Adverse events • Enrollment closed • Serious adverse event • Trial completion date • Chronic Kidney Disease • Nephrology • Renal Disease

Antidepressant composition change before bipolar disorder diagnosis among patients initially diagnosed with major depressive disorder. (PubMed, J Affect Disord) - "The duloxetine composition-change signal was not confined to the immediate 180-day prediagnostic period, whereas paroxetine and escitalopram signals were observed only in that period. These diagnosis-preceding prescribing patterns remain susceptible to protopathic bias and should not be interpreted as causal medication effects."

Journal • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Subclinical Hyperthyroidism Due to Graves’ Disease and a Large Mixed Hyperfunctioning Nodule: An Atypical Case of Marine-Lenhart Syndrome (ETA 2026) - "She was under metformin, fenofibrate, magnesium, cholecalciferol, and escitalopram...Methimazole 2.5mg once daily was initiated... MLS should be considered in patients with nodular goiter and biochemical hyperthyroidism, even when hormone excess is mild. Careful integration of ultrasound findings, immunological markers, and scintigraphy is essential for accurate diagnosis and optimal management."

Clinical • CNS Disorders • Depression • Dyslipidemia • Endocrine Disorders • Grave’s Disease • Idiopathic Arthritis • Immunology • Lipodystrophy • Metabolic Disorders • Polyendocrine Metabolic Ovarian Syndrome

Association Between CYP450 Polymorphisms and Treatment Outcomes of Escitalopram and Venlafaxine in Patients with Post Stroke Depression. (PubMed, Neuropsychiatr Dis Treat) - "These findings underscore the need for further exploration into the clinical utility of pharmacogenetics. Future antidepressant treatment should prioritize cost-effective, pragmatic approaches over costly genetic testing alone."

Journal • Cardiovascular • CNS Disorders • Depression • Mood Disorders • Psychiatry • CYP2C19 • CYP2D6

Effects of Escitalopram on Neuropsychiatric Symptoms in Alzheimer Disease: A Secondary Analysis From the S-CitAD Study. (PubMed, Am J Geriatr Psychiatry) - "Escitalopram may have an impact on the severity of symptoms of depression/dysphoria in AD. No new symptoms of hallucinations in the escitalopram group throughout the 12 week trial suggest a possible direction for future research into selective serotonin reuptake inhibitors (SSRIs) and the treatment and/or delaying of psychotic symptoms in AD. As this was an exploratory analysis involving multiple comparisons, findings may be spurious."

Journal • Alzheimer's Disease • CNS Disorders • Depression • Psychiatry

Successful management of trichotillomania in a patient with SSRI-induced hypersomnia: a case report. (PubMed, Front Psychiatry) - "A 25-year-old female medical student with a 13-year history of severe, stress-triggered Trichotillomania developed debilitating hypersomnia (16-18 hours of sleep/day) during separate trials of fluoxetine and escitalopram. This case suggests that a combined treatment approach incorporating bupropion and mindfulness-based behavioral therapy may be associated with sustained improvement in trichotillomania when SSRIs are poorly tolerated. Although the individual contribution of each intervention cannot be determined from a single case, this report adds to the limited literature supporting further investigation of non-serotonergic pharmacological strategies in selected patients."

Journal • Sleep Disorder

ELISA: Escitalopram and Language Intervention for Subacute Aphasia (clinicaltrials.gov) - P2 | N=88 | Recruiting | Sponsor: Johns Hopkins University | Trial completion date: Jan 2027 ➔ Jun 2027 | Trial primary completion date: Sep 2026 ➔ Feb 2027

Trial completion date • Trial primary completion date • Cardiovascular

Reinstatement of escitalopram and clonidine administration reverses the cessation-induced enhanced activation of rat norepinephrine and serotonin neuronal firing activity. (PubMed, J Psychopharmacol) - "These results show that abrupt cessation of the SRI escitalopram resulted in robust overactivation of both NE and 5-HT neurons. Normalization of the SRI cessation-induced overactivation of NE and 5-HT neurons by the acute inhibition of the 5-HT reuptake transporter is consistent with the rapid relief of discontinuation symptoms observed in patients resuming their SRI. A similar effect of clonidine on NE and 5-HT neuronal firing would support its use in managing discontinuation symptoms seen after SRI cessation."

Journal

Differential signal strength of male sexual dysfunction associated with antidepressants: a disproportionality analysis of FAERS database. (PubMed, Sex Med) - "Sertraline had the highest number of MSD (988 cases), accounting for 6.22% of its total 15 875 cases. Escitalopram showed the strongest signal on all 4 algorithms [ROR: 13.67, PRR: 13.19, lower limit of 95% CI of empirical Bayes geometric mean (EBGM05): 12.19, lower limit of 95% CI of the information component (IC025): 3.59]...Among the 28 antidepressants analyzed, 18 demonstrated significant associations with MSD. Beyond traditional selective serotonin reuptake inhibitors, the signal strength of MSD associated with other classes of antidepressants should not be overlooked."

Journal • CNS Disorders • Sexual Disorders

TNA-LBP: Treating Negative Affect in Low Back Pain Patients (clinicaltrials.gov) - P2 | N=308 | Completed | Sponsor: Ajay Wasan, MD, Msc | Phase classification: P2/3 ➔ P2

Phase classification • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain